Don Panoz, founder of Mylan, talks to CNBC exclusively about how electric race cars can be designed to be just as efficient on the track.
Mylan for years had classified EpiPen as a generic product, which are assessed lower rebate rates than brand-name drugs.
CNBC's Meg Tirrell reports on comments from Sen. Chuck Grassley on the cost of the Epipen to U.S. taxpayers.